Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07456059 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate EDG-7500 in Caucasian and Japanese Adults
A Phase 1 study, sponsored by Edgewise Therapeutics.
- Not yet
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT07456059: Clinical Trial Phase 1 study, sponsored by Edgewise Therapeutics.
NCT07456059 is a Phase 1 study that has not yet begun recruiting, run by Edgewise Therapeutics. The registered enrollment target is 24 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (60% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07456059, a Phase 1 study, has not yet begun recruiting, sponsored by Edgewise Therapeutics.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this Phase 1 study is to understand and compare the amount of EDG-7500 in the blood after single and multiple doses in Japanese and Caucasian adults. The safety of EDG-7500 in these adult participants will also be evaluated in this study.
Primary Outcome
Area under the plasma concentration time-curve from time zero to the last measured concentration
Interventions
- DRUG EDG-7500
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2026-03 |
| Est. Completion | 2026-06 |
| Phase | Phase 1 |
What is known before NCT07456059 opens enrollment
NCT07456059 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (60% lower).
The record links to 0 conditions, and to 1 intervention - of which EDG-7500 is the first listed.
NCT07456059 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07456059 about?
NCT07456059 is a clinical study titled "A Study to Evaluate EDG-7500 in Caucasian and Japanese Adults". The purpose of this Phase 1 study is to understand and compare the amount of EDG-7500 in the blood after single and multiple doses in Japanese and Caucasian adults. The safety of EDG-7500 in these adult participants will also be evaluated in this study.
What is the current status of trial NCT07456059?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2026-03. Estimated completion is 2026-06.
What interventions are being tested in trial NCT07456059?
The interventions under investigation include: EDG-7500 (DRUG).
Who is sponsoring clinical trial NCT07456059?
This trial is sponsored by Edgewise Therapeutics, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07456059's enrollment target sits among peer trials
24 1520th of 2000 higher than 405 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia